Raymond James Financial Services Advisors Inc. cut its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 7.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 409,580 shares of the biopharmaceutical company’s stock after selling 33,334 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Bristol-Myers Squibb were worth $21,290,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Bristol-Myers Squibb by 1.0% in the third quarter. Vanguard Group Inc. now owns 128,376,159 shares of the biopharmaceutical company’s stock valued at $7,969,593,000 after purchasing an additional 1,229,553 shares in the last quarter. Vanguard Group Inc boosted its holdings in Bristol-Myers Squibb by 1.0% in the third quarter. Vanguard Group Inc now owns 128,376,159 shares of the biopharmaceutical company’s stock valued at $7,969,593,000 after purchasing an additional 1,229,553 shares in the last quarter. BlackRock Inc. boosted its holdings in Bristol-Myers Squibb by 0.9% in the fourth quarter. BlackRock Inc. now owns 115,573,078 shares of the biopharmaceutical company’s stock valued at $6,007,489,000 after purchasing an additional 999,193 shares in the last quarter. Dodge & Cox boosted its holdings in Bristol-Myers Squibb by 0.8% in the third quarter. Dodge & Cox now owns 32,969,186 shares of the biopharmaceutical company’s stock valued at $2,046,727,000 after purchasing an additional 264,100 shares in the last quarter. Finally, Primecap Management Co. CA boosted its holdings in Bristol-Myers Squibb by 4.8% in the third quarter. Primecap Management Co. CA now owns 18,906,694 shares of the biopharmaceutical company’s stock valued at $1,173,728,000 after purchasing an additional 862,900 shares in the last quarter. 73.14% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE BMY opened at $49.19 on Thursday. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.61 and a quick ratio of 1.50. Bristol-Myers Squibb Co has a twelve month low of $44.30 and a twelve month high of $66.99. The company has a market capitalization of $80.98 billion, a price-to-earnings ratio of 12.36, a PEG ratio of 2.53 and a beta of 0.81.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.09. Bristol-Myers Squibb had a return on equity of 48.99% and a net margin of 21.95%. The company had revenue of $5.97 billion during the quarter, compared to analysts’ expectations of $5.95 billion. During the same quarter in the previous year, the business earned $0.68 earnings per share. The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Bristol-Myers Squibb Co will post 4.15 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be paid a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a yield of 3.33%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is currently 41.21%.

A number of brokerages recently issued reports on BMY. ValuEngine raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Friday, December 7th. Bank of America lowered their price target on Bristol-Myers Squibb from $53.00 to $51.00 and set a “neutral” rating for the company in a report on Tuesday, February 19th. BMO Capital Markets upped their price target on Bristol-Myers Squibb to $62.00 and gave the company an “outperform” rating in a report on Wednesday. Morgan Stanley set a $54.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Thursday, December 20th. Finally, Zacks Investment Research downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Thursday, January 3rd. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $59.59.

COPYRIGHT VIOLATION NOTICE: This piece of content was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2019/03/21/raymond-james-financial-services-advisors-inc-has-21-29-million-stake-in-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Recommended Story: How to calculate the intrinsic value of a stock

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.